While Samsung Biologics has decided to consign the Corona 19 vaccine for US pharmaceutical company Modena, the government has decided to proceed with consultations so that the consignment product can be supplied to Korea.
Jung Eun-young, head of the vaccine introduction secretary at the Central Accident Control Headquarters, said at a briefing at the'Korea-US Vaccine Cooperation' briefing, "We plan to discuss with pharmaceutical companies so that domestic products are supplied to Korea in terms of distribution efficiency."
Director Jung said, "Modena's (existing) contract is supposed to be supplied in the form of finished products produced overseas." I will do it," he explained.
Samsung Biologics and Moderna signed a contract for consignment production of vaccines through the'Korea-US Vaccine Partnership' held in Washington, DC the day before.
In the future, after technology transfer and trial production, mass production of modders and vaccines in Korea will be carried out in the third quarter.
Samsung Biologics will produce hundreds of millions of doses and supply them all over the world by ``full filling'' of Modna's COVID-19 vaccine in a form that can be administered to the human body.
Meanwhile, the government has announced that the contracted modder or vaccine will be introduced as planned, apart from the consignment production of Samsung Biologics.
Gang-tae, the second vice minister of the Ministry of Health and Welfare, said, "The modders or vaccines introduced in Korea will be introduced according to the contracted schedule regardless of the consignment and production timing.